Literature DB >> 22030095

Recombinant HDL(Milano) exerts greater anti-inflammatory and plaque stabilizing properties than HDL(wild-type).

Borja Ibanez1, Chiara Giannarelli, Giovanni Cimmino, Carlos G Santos-Gallego, Matilde Alique, Antonio Pinero, Gemma Vilahur, Valentin Fuster, Lina Badimon, Juan J Badimon.   

Abstract

OBJECTIVE: The aim of this study was to compare the effects of HDL(Milano) and HDL(wild-type), on regression and stabilization of atherosclerosis.
METHODS: Atherosclerotic New Zealand White rabbits received 2 infusions, 4 days apart, of HDL(Milano) (75mg/kg of apoA-I(Milano)), HDL(wild-type) (75mg/kg apoA-I(wild-type)) or placebo. Pre- and post-treatment plaque volume was assessed by MRI. Markers of plaque vulnerability and inflammation were evaluated. Liver and aortic cholesterol content, aortic ABCA-1 and liver SR-BI were quantified. The effect of apoA-I Milano and wild-type proteins on MCP-1 and COX-2 expression by macrophages was evaluated in vitro.
RESULTS: Both forms of HDL induced aortic plaque regression (-4.1% and -2.6% vs. pre-treatment in HDL(Milano) and HDL(wild-type) respectively, p<0.001 and p=0.009). A similar reduction in cholesterol content of aorta and liver was observed with both treatments vs. placebo. The expression of aortic ABCA-1 and hepatic SR-BI was significantly higher in both treated groups vs. placebo. A significantly reduced plaque macrophage density was observed in the HDL(Milano) vs. both HDL(wild-type) and placebo groups. Plaque levels of COX-2, MCP-1, Caspase-3 antigen and MMP-2 activity were significantly reduced in the HDL(Milano) vs. both HDL(wild-type) and placebo groups. In vitro studies showed that apoA-I(Milano) protein significantly reduced expression of COX-2 and MCP-1 in oxLDL loaded macrophages vs. apoA-I(wild-type).
CONCLUSIONS: Despite a similar effect on acute plaque regression, the infusion of HDL(Milano) exerts superior anti-inflammatory and plaque stabilizing effects than HDL(wild-type) in the short term.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22030095     DOI: 10.1016/j.atherosclerosis.2011.10.006

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  30 in total

Review 1.  Genetics of HDL-C: a causal link to atherosclerosis?

Authors:  Julian C van Capelleveen; Andrea E Bochem; M Mahdi Motazacker; G Kees Hovingh; John J P Kastelein
Journal:  Curr Atheroscler Rep       Date:  2013-06       Impact factor: 5.113

Review 2.  HDL dysfunction in diabetes: causes and possible treatments.

Authors:  Dan Farbstein; Andrew P Levy
Journal:  Expert Rev Cardiovasc Ther       Date:  2012-03

3.  Anti-Inflammatory Effects of HDL (High-Density Lipoprotein) in Macrophages Predominate Over Proinflammatory Effects in Atherosclerotic Plaques.

Authors:  Panagiotis Fotakis; Vishal Kothari; David G Thomas; Marit Westerterp; Matthew M Molusky; Elissa Altin; Sandra Abramowicz; Nan Wang; Yi He; Jay W Heinecke; Karin E Bornfeldt; Alan R Tall
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-10-03       Impact factor: 8.311

Review 4.  High-density lipoprotein: a novel target for antirestenosis therapy.

Authors:  Kai Yin; Devendra K Agrawal
Journal:  Clin Transl Sci       Date:  2014-07-15       Impact factor: 4.689

5.  [A high level of high-density lipoprotein cholesterol is a protective factor against transplant renal artery stenosis].

Authors:  Yan-Na Liu; Li-Xin Yu; Wen-Feng Deng; Kai-Qun Li; Ru-Min Liu; Gui-Rong Ye; Fang-Xiang Fu; Jiang-Tao Li; Yun Miao
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-02-20

6.  The apoA-I mimetic peptide 4F protects apolipoprotein A-I from oxidative damage.

Authors:  C Roger White; Geeta Datta; Landon Wilson; Mayakonda N Palgunachari; G M Anantharamaiah
Journal:  Chem Phys Lipids       Date:  2019-01-29       Impact factor: 3.329

Review 7.  High-density lipoprotein mimetics: promises and challenges.

Authors:  Dmitri Sviridov; Alan T Remaley
Journal:  Biochem J       Date:  2015-12-15       Impact factor: 3.857

Review 8.  ApoA-I-Directed Therapies for the Management of Atherosclerosis.

Authors:  John S Millar; Marina Cuchel
Journal:  Curr Atheroscler Rep       Date:  2015-10       Impact factor: 5.113

Review 9.  Molecules that mimic apolipoprotein A-I: potential agents for treating atherosclerosis.

Authors:  Luke J Leman; Bruce E Maryanoff; M Reza Ghadiri
Journal:  J Med Chem       Date:  2013-10-29       Impact factor: 7.446

10.  ApoL1 levels in high density lipoprotein and cardiovascular event presentation in patients with familial hypercholesterolemia.

Authors:  Judit Cubedo; Teresa Padró; Rodrigo Alonso; Pedro Mata; Lina Badimon
Journal:  J Lipid Res       Date:  2016-04-25       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.